Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Frontiers in Health Policy Research
|
December 23, 2004
Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand
Patricia M Danzon, Jonathan D Ketcham
Health Affairs (Project Hope)
|
October 28, 2004
Prices and availability of pharmaceuticals: evidence from nine countries
Patricia M Danzon, Michael F Furukawa
Journal of Health Economics
|
August 18, 2000
Cross-national price differences for pharmaceuticals: how large, and why?
P M Danzon, L W Chao
Cancer Detection and Prevention
|
January 1, 1995
Is tobacco use finally decreasing in France?
A J Sasco, D Grizeau, M Danzon
Health Economics
|
September 24, 2004
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
Patricia M Danzon, Y Richard Wang, Liang Wang
Journal of Health Economics
|
February 22, 2005
Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
Patricia M Danzon, Sean Nicholson, Nuno Sousa Pereira
Health Affairs (Project Hope)
|
August 9, 2011
Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries
Patricia M Danzon, Adrian Towse, Andrew W Mulcahy
Health Care Financing Review
|
February 4, 1985
Factors affecting laboratory test use and prices
P M Danzon, W G Manning, M S Marquis
The American Economic Review
|
April 9, 1990
Incentive effects of medical malpractice. The effects of malpractice litigation on physicians' fees and incomes
P M Danzon, M V Pauly, R S Kington
The American Journal of Managed Care
|
March 25, 2005
Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond
Patricia M Danzon, Gail R Wilensky, Kathleen E Means
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Frontiers in Health Policy Research
|
December 23, 2004
Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand
Patricia M Danzon, Jonathan D Ketcham
Health Affairs (Project Hope)
|
October 28, 2004
Prices and availability of pharmaceuticals: evidence from nine countries
Patricia M Danzon, Michael F Furukawa
Journal of Health Economics
|
August 18, 2000
Cross-national price differences for pharmaceuticals: how large, and why?
P M Danzon, L W Chao
Cancer Detection and Prevention
|
January 1, 1995
Is tobacco use finally decreasing in France?
A J Sasco, D Grizeau, M Danzon
Health Economics
|
September 24, 2004
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
Patricia M Danzon, Y Richard Wang, Liang Wang
Journal of Health Economics
|
February 22, 2005
Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
Patricia M Danzon, Sean Nicholson, Nuno Sousa Pereira
Health Affairs (Project Hope)
|
August 9, 2011
Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries
Patricia M Danzon, Adrian Towse, Andrew W Mulcahy
Health Care Financing Review
|
February 4, 1985
Factors affecting laboratory test use and prices
P M Danzon, W G Manning, M S Marquis
The American Economic Review
|
April 9, 1990
Incentive effects of medical malpractice. The effects of malpractice litigation on physicians' fees and incomes
P M Danzon, M V Pauly, R S Kington
The American Journal of Managed Care
|
March 25, 2005
Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond
Patricia M Danzon, Gail R Wilensky, Kathleen E Means
Page
of 6